HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock

Posted by Trevor Kearing on Mar 24th, 2025

Enlivex Therapeutics (NASDAQ:ENLV – Get Free Report) had its target price lifted by analysts at HC Wainwright from $6.00 to $7.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $13.00 target price on shares of Enlivex Therapeutics in a report on Monday, March 3rd.

Get Our Latest Analysis on Enlivex Therapeutics

Enlivex Therapeutics Trading Down 4.1 %

Shares of NASDAQ ENLV opened at $1.05 on Monday. Enlivex Therapeutics has a twelve month low of $0.81 and a twelve month high of $4.59. The stock has a market cap of $22.37 million, a P/E ratio of -1.07 and a beta of 1.11. The stock has a 50 day moving average of $1.10 and a two-hundred day moving average of $1.24.

Institutional Investors Weigh In On Enlivex Therapeutics

Institutional investors have recently made changes to their positions in the stock. Millennium Management LLC purchased a new position in shares of Enlivex Therapeutics in the 4th quarter valued at about $742,000. Two Sigma Securities LLC acquired a new position in Enlivex Therapeutics during the fourth quarter worth about $26,000. Finally, Renaissance Technologies LLC increased its holdings in Enlivex Therapeutics by 112.6% in the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after buying an additional 84,203 shares in the last quarter. 1.02% of the stock is currently owned by hedge funds and other institutional investors.

About Enlivex Therapeutics

(Get Free Report)

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.